1. Home
  2. LEVI vs PODD Comparison

LEVI vs PODD Comparison

Compare LEVI & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Levi Strauss & Co

LEVI

Levi Strauss & Co

HOLD

Current Price

$21.34

Market Cap

9.6B

ML Signal

HOLD

Logo Insulet Corporation

PODD

Insulet Corporation

HOLD

Current Price

$143.81

Market Cap

10.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEVI
PODD
Founded
1853
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
10.3B
IPO Year
2019
2007

Fundamental Metrics

Financial Performance
Metric
LEVI
PODD
Price
$21.34
$143.81
Analyst Decision
Strong Buy
Buy
Analyst Count
12
21
Target Price
$26.92
$341.48
AVG Volume (30 Days)
1.7M
1.7M
Earning Date
04-07-2026
05-06-2026
Dividend Yield
2.56%
N/A
EPS Growth
178.85
N/A
EPS
0.67
2.67
Revenue
$6,282,000,000.00
$2,708,100,000.00
Revenue This Year
$8.64
$24.55
Revenue Next Year
$4.82
$19.18
P/E Ratio
$31.48
$53.58
Revenue Growth
N/A
30.73
52 Week Low
$17.72
$126.40
52 Week High
$25.70
$354.88

Technical Indicators

Market Signals
Indicator
LEVI
PODD
Relative Strength Index (RSI) 29.02 41.23
Support Level $20.41 $139.23
Resistance Level $22.45 $170.20
Average True Range (ATR) 0.59 5.25
MACD -0.21 -0.15
Stochastic Oscillator 7.08 28.65

Price Performance

Historical Comparison
LEVI
PODD

About LEVI Levi Strauss & Co

Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Share on Social Networks: